Health and Human Services Secretary Robert F. Kennedy Jr. rolled out a federal push aimed at reducing the use of certain psychiatric drugs, framing the move as addressing overprescribing in the U.S. mental health system. Speaking at a mental health summit hosted by the Make America Healthy Again Institute, Kennedy said the initiative would promote “deprescribing”—the supervised reduction or discontinuation of medications, particularly among children.
The initiative will prioritize “patient autonomy,” along with “informed consent and shared decision-making,” while trying to move care toward “prevention, transparency and a more holistic approach to mental health,” according to Kennedy. According to the Centers for Disease Control and Prevention, about 16.5% of U.S. adults reported taking medication for mental health conditions in 2020.
As part of the initiative, the Substance Abuse and Mental Health Services Administration will produce a report analyzing national prescribing patterns. HHS leadership circulated a “Dear Colleague” letter arguing that psychiatric drugs “should not be understood as the only treatment option.” The Eli Lilly medications Prozac and Cymbalta are among the widely prescribed drugs for depression and anxiety that may be subject to increased scrutiny.
The effort represents a significant shift in federal mental health policy, addressing concerns about the long-term consequences of psychiatric medication reliance while promoting alternative approaches to treatment and recovery.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/news/health-care/26/05/52311046/rfk-jr-psychiatric-drugs-deprescribing-push-big-pharma-warning